May 3, 2024

The Scent of Hope: Innovative Treatment Restores Sense of Smell in Patients With Long COVID

” Other treatments have stopped working to date. This injection is working.”– Dr. Adam C. Zoga

The distorted sense of smell can likewise affect smell perception, and some clients may struggle with phantosmia, a condition that causes people to spot smells– nasty or pleasant– that arent in their environment.
New Treatment Restores Sense of Smell in Patients With Long COVID Infographic. Credit: RSNA
Potential Treatment
To assess a possible treatment for clients with long-term post-COVID parosmia, researchers took a look at the possible benefits of CT-guided stellate ganglion block. Part of the free nerve system, which regulates involuntary processes including heart rate, blood pressure, breathing, and food digestion, the stellate ganglia are nerves on each side of the neck. They provide certain signals to the head, neck, arms, and a part of the upper chest.

A brand-new minimally invasive treatment utilizing CT-guided stellate ganglion block shows guarantee in restoring the sense of smell in long-COVID patients with parosmia. Early arise from a research study involving 54 patients suggest significant symptom improvement, marking a prospective development in treating this COVID-19-related condition.
Using an image-guided minimally invasive treatment, researchers may be able to restore the sense of smell in clients who have experienced long-COVID, according to research existing today at the annual conference of the Radiological Society of North America (RSNA).
Comprehending Parosmia
Parosmia, a condition where the sense of odor no longer works properly, is a recognized symptom of COVID-19. Current research study has actually found that approximately 60% of COVID-19 patients have actually been impacted. While the majority of clients do recover their sense of smell over time, some patients with long COVID continue to have these symptoms for months, and even years, after infection, negatively affecting their hunger for food and their total quality of life.
” Post-COVID parosmia prevails and significantly acknowledged,” said the studys lead author, Adam C. Zoga, M.D., M.B.A., teacher of musculoskeletal radiology at Jefferson Health in Philadelphia, Pennsylvania. “Patients can establish a distaste for drinks and foods they used to enjoy.”

The research study team used a stellate ganglion block, that includes injecting anesthetic directly into the stellate ganglion on one side of the neck to stimulate the regional free worried system. The minimally intrusive procedure takes less than 10 minutes, and no sedation or intravenous analgesia is required. Stellate ganglion block has actually been used with differing degrees of success to treat a number of conditions, consisting of cluster headaches, phantom limb pain, Raynauds and Menieres syndromes, angina, and heart arrhythmia.
” Parosmia has formerly been reported as a rare condition taking place after brain injury, brain surgery, stroke, viral syndromes, and with some head and neck tumors,” Dr. Zoga stated. “We were not completely positive that the treatment would work for parosmia.”
Research study and Outcomes
For the research study, 54 patients were referred from a nose, throat, and ear expert after a minimum of six months of post-COVID parosmia that was resistant to pharmaceutical and topical therapies.
CT assistance was used to position a spinal needle at the base of the neck for injection into the stellate ganglion. The researchers included a small dose of corticosteroid to the anesthetic in the pharmacologic preparation, presuming that the COVID infection may be triggering nerve inflammation.
” The initial patient had a significantly positive result, practically immediately, with continued improvement to the point of symptom resolution at four weeks,” Dr. Zoga stated. “We have actually been shocked at some results, consisting of near 100% resolution of phantosmia in some clients, throughout the trial.”
Follow-up was gotten for 37 patients (65%), with 22 (59%) of the 37 reporting improved signs at one week post-injection. Of these 22, 18 (82%) reported significant progressive enhancement by one month post-procedure. At 3 months, there was a mean 49% improvement in signs (range 10% to 100%) among the 22 patients.
Twenty-six clients returned for a 2nd injection provided on the other side (contralateral) of their neck after at least a six-week period. While the 2nd injection was ineffective in patients who did not react to the very first injection, 86% of clients who reported some enhancement after the first injection reported extra improvement after the contralateral injection. No issues or negative occasions were reported.
” Other treatments have stopped working to date,” Dr. Zoga stated. “This injection is working.”
Co-authors are Sarah I. Kamel, M.D., T. Rohan, M. A. Moriarty, Johannes B. Roedl, Ph.D., M.D., Vishal Desai, M.D., and Jeffrey A. Belair, M.D.

While a lot of clients do recuperate their sense of odor over time, some clients with long COVID continue to have these symptoms for months, or even years, after infection, negatively impacting their appetite for food and their overall quality of life.
To examine a possible treatment for patients with long-lasting post-COVID parosmia, researchers looked at the possible advantages of CT-guided stellate ganglion block. Follow-up was acquired for 37 patients (65%), with 22 (59%) of the 37 reporting enhanced signs at one week post-injection. At 3 months, there was a mean 49% enhancement in signs (range 10% to 100%) among the 22 clients.
While the second injection was not reliable in clients who did not react to the first injection, 86% of patients who reported some enhancement after the first injection reported additional enhancement after the contralateral injection.